Alto Neuroscience uses AI to create biomarkers for personalised mental health drugs
GlobalData’s Drugs Database reveals that more than 490 unique drugs have been discovered using AI-based technologies.
By
GlobalData’s Drugs Database reveals that more than 490 unique drugs have been discovered using AI-based technologies.
ByAccording to Mental Health, 14.7% of individuals develop mental health disorders in the workplace, a trend increased by Covid-19.
ByThe application is supported by data from two Phase III clinical trials of TV46000 in schizophrenia patients aged 13 to…
Data from recent studies reinforce the evidence that suggests maternal smoking during pregnancy is a risk factor for Tourette syndrome.
ByFDA has granted approval for Alkermes’ Lybalvi for treating schizophrenia in adults and helping with bipolar I disorder.
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it…
ByNovartis has entered into a definitive agreement to acquire all of the outstanding capital stock of US-based neuroscience company Cadent…
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor…
Thank you for subscribing to Pharmaceutical Technology